Tripoint Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TRIPOINT, and when can generic versions of TRIPOINT drugs launch?
TRIPOINT has one approved drug.
There are five US patents protecting TRIPOINT drugs.
There are twenty-three patent family members on TRIPOINT drugs in eighteen countries and two supplementary protection certificates in two countries.
Summary for Tripoint
| International Patents: | 23 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Tripoint
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,425,938 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,163,306 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,535,717 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Tripoint | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | RX | Yes | Yes | 8,535,717 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tripoint Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 174396 | See Plans and Pricing |
| European Patent Office | 1663175 | See Plans and Pricing |
| South Africa | 200602276 | See Plans and Pricing |
| Poland | 381756 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tripoint Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0162036 | C300028 | Netherlands | See Plans and Pricing | PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929 |
| 0162036 | 2000C/032 | Belgium | See Plans and Pricing | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
